<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04740801</url>
  </required_header>
  <id_info>
    <org_study_id>PM011</org_study_id>
    <nct_id>NCT04740801</nct_id>
  </id_info>
  <brief_title>Electrical Coupling Information From The RHYTHMIA HDx Mapping System and DIRECTSENSE Technology In The Treatment of Paroxysmal Atrial Fibrillation (LOCALIZE CF)</brief_title>
  <acronym>LOCALIZE CF</acronym>
  <official_title>Electrical Coupling Information From The RHYTHMIA HDx Mapping System and DIRECTSENSE Technology In The Treatment of Paroxysmal Atrial Fibrillation: A Non-Randomized Prospective Study With Contact Force</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate whether local impedance (DIRECTSENSE™) drop on the&#xD;
      INTELLANAV STABLEPOINT™ ablation catheter is associated with late pulmonary vein (PV)&#xD;
      reconnections and durable conduction block in patients undergoing de novo PV isolation (PVI)&#xD;
      for treatment of paroxysmal atrial fibrillation (PAF).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 29, 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Association between Local Impedance drop values and PV reconnections</measure>
    <time_frame>0-3 months</time_frame>
    <description>Correlation between local impedance drop collected during the blinded index procedure and sites of late PV reconnection/durable block at 3-months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Association between Local Impedance drop values and acute PV reconnections</measure>
    <time_frame>0-1 month</time_frame>
    <description>Correlation between local impedance drop collected during the blinded index procedure and sites of acute gaps/block after a 20-minute wait period.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Paroxysmal Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>PVI procedure</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects will undergo ablation treatment of the pulmonary veins with the Rhythmia HDx mapping system with DirectSense technology. Subjects indicated for ablation treatment of de-novo PAF will be selected based on the inclusion/exclusion criteria and if deemed to be eligible for participation, will be asked to sign the Informed Consent Form. For all enrolled subjects who undergo the ablation procedure, the subjects will be treated with the commercial Rhythmia HDx System with commercially available Software Version 4.0.1 or greater (commercially approved version) with DIRECTSENSE™ and Force Computation Software Module; the IntellaMap Orion mapping catheter and the IntellaNav StablePoint ablation catheter.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ablation procedure</intervention_name>
    <description>Catheter ablation of pulmonary veins with the Rhythmia HDx mapping system, IntellaMap Orion mapping catheter and IntellaNav StablePoint ablation catheter</description>
    <arm_group_label>PVI procedure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. History of recurrent, symptomatic, paroxysmal atrial fibrillation (PAF), defined as&#xD;
             atrial fibrillation (AF) that terminates spontaneously or with intervention (either&#xD;
             procedure or drug therapy) within seven days of onset. Minimum documentation includes&#xD;
             at least one AF episode electrocardiographically documented and at least one&#xD;
             additional symptomatic recurrence with or without electrocardiographic documentation,&#xD;
             within 365 days prior to enrollment.&#xD;
&#xD;
          2. Subjects who are eligible for an ablation procedure for paroxysmal AF according to&#xD;
             international and local guidelines on catheter ablation of AF.&#xD;
&#xD;
          3. Subjects refractory or intolerant to at least one Beta Blocker, Calcium Channel&#xD;
             Blocker, class I or III antiarrhythmic medication taken for the treatment of AF/AT&#xD;
             (Atrial Tachycardia)/AFL (Atrial Flutter) or contraindicated to any class I or III&#xD;
             antiarrhythmic medications, Beta Blocker or Calcium Channel Blocker.&#xD;
&#xD;
          4. Subjects who are willing and capable of providing informed consent.&#xD;
&#xD;
          5. Subjects who are willing and capable of participating in all testing associated with&#xD;
             this clinical investigation at an approved clinical investigational center.&#xD;
&#xD;
          6. Subjects whose age is 18 years or above, or who are of legal age to give informed&#xD;
             consent specific to local and national law.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any known contraindication to an AF ablation or anticoagulation&#xD;
&#xD;
          2. Continuous AF lasting longer than seven days from onset (no episodes within 365 days&#xD;
             from enrollment)&#xD;
&#xD;
          3. History of previous LA ablation or surgical treatment for AF/AT/AFL&#xD;
&#xD;
          4. AF secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac&#xD;
             cause&#xD;
&#xD;
          5. Subjects with life expectancy ≤ 6 months&#xD;
&#xD;
          6. Structural heart disease, heart conditions, or implanted devices as described below:&#xD;
&#xD;
               1. Left ventricular ejection fraction &lt; 35% based on the most recent imaging (≤ 180&#xD;
                  days prior to enrollment)*&#xD;
&#xD;
               2. LA diameter &gt; 5.5 cm or LA volume &gt;50 ml/m² indexed based on the most recent&#xD;
                  imaging (≤ 180 days prior to enrollment)*&#xD;
&#xD;
               3. Heart failure with New York Heart Association (NYHA) Class III or IV&#xD;
&#xD;
               4. Previous cardiac surgery (e.g. ventriculotomy or atriotomy, CABG, PTCA, stent&#xD;
                  procedure) within 90 days prior to enrollment&#xD;
&#xD;
               5. Implantable cardiac device procedures (e.g. PM, ICD, CRT) within 30 days prior to&#xD;
                  enrollment&#xD;
&#xD;
               6. Severe valvular disease or presence of a prosthetic - mechanical or biological -&#xD;
                  heart valve in the LA (not including valve repair and annular rings)&#xD;
&#xD;
               7. Severe mitral valve regurgitation or stenosis&#xD;
&#xD;
               8. Known or pre-existing severe pulmonary vein stenosis&#xD;
&#xD;
               9. Interatrial baffle, closure device, patch, or patent foramen ovale (PFO) occluder&#xD;
&#xD;
              10. Presence of LA appendage occlusion device&#xD;
&#xD;
              11. Presence of any pulmonary vein stents&#xD;
&#xD;
              12. Unstable angina or ongoing myocardial ischemia&#xD;
&#xD;
              13. Previous myocardial infarction within 90 days prior to enrollment&#xD;
&#xD;
              14. Vena cava embolic protection filter devices and/or known femoral thrombus;&#xD;
&#xD;
              15. Known left atrial thrombus, myxoma, or intracardiac mural thrombus&#xD;
&#xD;
          7. History of blood clotting or bleeding disease&#xD;
&#xD;
          8. Any prior history of documented cerebral infarct, TIA, or systemic embolism [excluding&#xD;
             a post-operative deep vein thrombosis (DVT)] ≤180 days prior to enrollment&#xD;
&#xD;
          9. Active systemic infection&#xD;
&#xD;
         10. Pregnant, lactating (current or anticipated during study follow up), or women of&#xD;
             childbearing potential who are, or plan to become, pregnant during the time of the&#xD;
             study (method of assessment upon physician's discretion)&#xD;
&#xD;
         11. Subjects who are currently enrolled in any other concurrent study, with the exception&#xD;
             of local mandatory governmental registries and observational studies/registries,&#xD;
             without written approval from the sponsor&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ignacio Garcia Bolao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinica Universitaria de Navarra</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Moloy Das, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Freeman Health System</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gwilym Morris, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Manchester Heart Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alberto Belligoli</last_name>
    <phone>+39 342 199 4999</phone>
    <email>alberto.belligoli@bsci.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Giovanni Raciti</last_name>
    <phone>+393482502687</phone>
    <email>giovanni.raciti@bsci.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Vivantes Klinikum Am Urban</name>
      <address>
        <city>Berlin</city>
        <zip>10967</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hüseyin Ince</last_name>
    </contact>
    <contact_backup>
      <last_name>Niels Christian Ewertsen</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinikum Karlsruhe</name>
      <address>
        <city>Karlsruhe</city>
        <zip>76133</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Armin Luik</last_name>
    </contact>
    <contact_backup>
      <last_name>Kerstin Schmidt</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Clinica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jose Ignacio Gracia Bolao</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 2, 2021</study_first_submitted>
  <study_first_submitted_qc>February 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2021</study_first_posted>
  <last_update_submitted>July 6, 2021</last_update_submitted>
  <last_update_submitted_qc>July 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No requests for study data have been made at this time, however Boston's Scientific's policy on data sharing can be found at http:// www.bostonscientific.com/en-US/data-sharing-requests.html</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

